Refine
Has Fulltext
- yes (11)
Is part of the Bibliography
- yes (11)
Year of publication
Document Type
- Journal article (10)
- Doctoral Thesis (1)
Keywords
- adrenocortical carcinoma (5)
- CXCR4 (3)
- endoradiotherapy (3)
- theranostics (3)
- C-X-C motif chemokine receptor 4 (2)
- [68Ga]PentixaFor (2)
- chemokine receptor (2)
- Addisons disease (1)
- Adrenostatika (1)
- CCR7 (1)
Institute
- Medizinische Klinik und Poliklinik I (9)
- Klinik und Poliklinik für Nuklearmedizin (5)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
- Medizinische Klinik und Poliklinik II (2)
- Pathologisches Institut (2)
- Urologische Klinik und Poliklinik (2)
- Comprehensive Cancer Center Mainfranken (1)
- Medizinische Klinik (bis 2004) (1)
- Theodor-Boveri-Institut für Biowissenschaften (1)
EU-Project number / Contract (GA) number
- 259735 (1)
Adrenocortical carcinoma (ACC) represents a rare tumor entity with limited treatment options and usually rapid tumor progression in case of metastatic disease. As further treatment options are needed and ACC metastases are sensitive to external beam radiation, novel theranostic approaches could complement established therapeutic concepts. Recent developments focus on targeting adrenal cortex-specific enzymes like the theranostic twin [\(^{123/131}\)I]IMAZA that shows a good image quality and a promising therapeutic effect in selected patients. But other established molecular targets in nuclear medicine such as the C-X-C motif chemokine receptor 4 (CXCR4) could possibly enhance the therapeutic regimen as well in a subgroup of patients. The aims of this review are to give an overview of innovative radiopharmaceuticals for the treatment of ACC and to present the different molecular targets, as well as to show future perspectives for further developments since a radiopharmaceutical with a broad application range is still warranted.